RE: SAR30 Aug 2024 11:35
All the best with your investment Sheephatch.
@ All - there's always a lot of conjecture on a bb and none more so than here, but, things could be shaping up in the near future.
TM stepping down is no real biggie for me, as "succession" was spoke within the '22 AGM and post '23 AGM - I think given the MHRA reluctance to pursue Clinical trials, he probably postponed the move - And remember MHRA was a typical UK Gov. Dept bureaucratic fiasco, otherwise, how did Oz accept trials so quickly - so well done BoD for moving!
JR has explained that once Clinical trials of 1801 completed, there will be the Bio Marker correlation of blinded data in not only Psoriasis but other indications as well, again confirmed by TM in the RNS that a suitable data package formulated for next phase of development- I'm no scientist but I imagine very time consuming and that both JR and TM are on this now.
No doubt SP is talking with interested parties, all of whom will be interested in the various indications being analysed and good to see Sareum at the Stockholm Bio Europe in November "30 years of facilitating partnerships" - lets hope there's at least one in there for us - ultimately, it all rests on a great data package.
As for SRA 737, it's perfectly clear as stated in the RNS any update will be via CRUK/CRT, it's their negotiated Contract, not Sareum's.
Yes, I'm frustrated with the sp and have been so with communications, but, for once I'm prepared to hang on and let the BoD do it in their time and hopefully, get it bang on right!
Off for a couple of weeks, but, will still look in.
GLA